The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of extrachromosomal DNA (ecDNA) on MYCN amplified neuroblastoma and patient outcomes.
 
Mihika Sonalkar
No Relationships to Disclose
 
Carla Sampaio
No Relationships to Disclose
 
Ting Yang
No Relationships to Disclose
 
Taelor Getz
No Relationships to Disclose
 
Catherine Shaw
No Relationships to Disclose
 
Vicky Pham
No Relationships to Disclose
 
Joshua Lange
Employment - Boundless Bio
 
Sudhir Chowdhry
Employment - Boundless Bio
 
Christian Hassig
Employment - Boundless Bio
Leadership - Boundless Bio
 
Ludmil Alexandrov
Employment - bioTheranostics (I)
Leadership - io9 LLC
Stock and Other Ownership Interests - io9 LLC
Consulting or Advisory Role - Genome Insight; io9 LLC
Patents, Royalties, Other Intellectual Property - Inventor of a provisional patent application for utilizing clustered mutations as clinical biomarkers for cancer therapy (Inst); Inventor of a US Patent 10,776,718 for source identification by nonnegative matrix factorization. (Inst); Inventor of U.S. provisional patent application for Artificial intelligence architecture for predicting cancer biomarker (63/269,033 and 63/483,237). (Inst); Inventor of U.S. provisional patent application for Genetically-defined immune-checkpoint inhibitor resistance in aggressive precursors of HPV- head and neck squamous cancer (63/412,835). (Inst); Inventor of U.S. provisional patent application for Methods and systems for detecting homologous recombination deficiency in cancer therapies (63/366,392). (Inst); Products of manufacture for culturing or maintaining normal, pre-cancer and cancer stem and progenitor cells and methods of making and using them (PCT/US2023/010679) (Inst)
 
Peter Zage
Consulting or Advisory Role - Y-mAbs Therapeutics
Research Funding - Aptose Biosciences; Boundless Bio; Exelixis; QED Therapeutics